Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Visual impairment predominantly due to neovascular age-related macular degeneration AMD~* Active, newly diagnosed, untreated CNV due to AMD~* CNV involving the center of the retina~* A qualifying vision score at study entry~Exclusion Criteria:~* Stroke or myocardial infarction less than 3 Months prior to study entry~* Active injection or inflammation of either eye at the time of study entry

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RBZ 0.5 mg: VA only (Group I) (Type: EXPERIMENTAL): RBZ 0.5 mg: Visual Acuity (VA) only (Group I) 0.5 mg intravitreal injections of ranibizumab with retreatment based on best-corrected visual acuity (BCVA) loss due to neovascular (wet) age-related macular degeneration (nAMD)
- RBZ 0.5 mg: VA and/or OCT (Group II) (Type: EXPERIMENTAL): RBZ 0.5 mg: VA and/or OCT (Group II) 0.5 mg intravitreal injections of ranibizumab with retreatment based on best-corrected visual acuity (BCVA)loss due to neovascular (wet) age-related macular degeneration (nAMD) and/or signs of wet AMD disease activity on optical coherence tomography (OCT).

Based on this trial design, predict the completion outcome and termination type (if applicable).